Cargando…

Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy

BACKGROUND: The effects of first-line chemoradiotherapy on overall survival (OS) may be confounded by subsequent lines of therapy in patients with limited-stage disease small cell lung cancer (LD-SCLC). Therefore, we aimed to determine the relationships between progression-free survival (PFS), post-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kasahara, Norimitsu, Imai, Hisao, Kaira, Kyoichi, Mori, Keita, Wakuda, Kazushige, Ono, Akira, Taira, Tetsuhiko, Kenmotsu, Hirotsugu, Harada, Hideyuki, Naito, Tateaki, Murakami, Haruyasu, Endo, Masahiro, Nakajima, Takashi, Yamada, Masanobu, Takahashi, Toshiaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Versita, Warsaw 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722933/ https://www.ncbi.nlm.nih.gov/pubmed/26834529 http://dx.doi.org/10.1515/raon-2015-0037

Ejemplares similares

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2015)

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
por: Akamatsu, Hiroaki, et al.
Publicado: (2014)

Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2015)

Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy
por: Imai, Hisao, et al.
Publicado: (2015)

Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter
por: Watanabe, Masaru, et al.
Publicado: (2018)

Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities
por: Kobayashi, Haruki, et al.
Publicado: (2021)

Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy
por: Kobayashi, Haruki, et al.
Publicado: (2018)

Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure
por: Kawamura, Takahisa, et al.
Publicado: (2016)

The effects of advanced age and serum α(1)‐acid glycoprotein on docetaxel unbound exposure and dose‐limiting toxicity in cancer patients
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2017)

Primary malignant melanoma of the trachea: A case report
por: IMAI, HISAO, et al.
Publicado: (2015)

Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation
por: Kawamura, Takahisa, et al.
Publicado: (2019)

Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients
por: Ko, Ryo, et al.
Publicado: (2016)

Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study
por: Ono, Akira, et al.
Publicado: (2013)

Acquired immunodeficiency associated with thymoma: a case report
por: Kawamura, Takahisa, et al.
Publicado: (2019)

Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: A single-center retrospective study
por: Mitsuya, Koichi, et al.
Publicado: (2019)

Efficacy of prophylactic cranial irradiation in patients with limited-disease small-cell lung cancer who were confirmed to have no brain metastasis via magnetic resonance imaging after initial chemoradiotherapy
por: Mamesaya, Nobuaki, et al.
Publicado: (2018)

Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study
por: Naito, Tateaki, et al.
Publicado: (2017)

Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non–small-cell lung cancer
por: Naito, Tateaki, et al.
Publicado: (2017)

Proposing synchronous oligometastatic non–small‐cell lung cancer based on progression after first‐line systemic therapy
por: Miyawaki, Taichi, et al.
Publicado: (2020)

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
por: Miyawaki, Taichi, et al.
Publicado: (2021)

Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide
por: Imai, Hisao, et al.
Publicado: (2016)

Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status
por: Mamesaya, Nobuaki, et al.
Publicado: (2023)

Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis
por: Takinami, Masaki, et al.
Publicado: (2021)

Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer
por: Inoue, Hiroto, et al.
Publicado: (2020)

Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
por: Miyawaki, Taichi, et al.
Publicado: (2020)

Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non‐small cell lung cancer
por: Nishioka, Naoya, et al.
Publicado: (2020)

Clinical impact of post‐progression survival on overall survival in elderly patients with extensive disease small‐cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2016)

Clinical impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer
por: Miyawaki, Taichi, et al.
Publicado: (2022)

Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
por: Nishimura, Ari, et al.
Publicado: (2021)

Predicting the efficacy of first‐line immunotherapy by combining cancer cachexia and tumor burden in advanced non‐small cell lung cancer
por: Miyawaki, Taichi, et al.
Publicado: (2022)

Clinical significance of post‐progression survival in lung cancer
por: Imai, Hisao, et al.
Publicado: (2017)

A favorable clinical effect of an expectorant in allergic bronchopulmonary mycosis caused by Schizophyllum commune
por: Kobayashi, Haruki, et al.
Publicado: (2016)

Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation
por: Kodama, Hiroaki, et al.
Publicado: (2021)

Incidence and Treatment Outcome of Radiation Pneumonitis in Patients With Limited-stage Small Cell Lung Cancer Treated With Concurrent Accelerated Hyperfractionated Radiation Therapy and Chemotherapy
por: Doshita, Kosei, et al.
Publicado: (2022)

Clinical Impact of Post-progression Survival in Patients with Locally Advanced Non-small Cell Lung Cancer After Chemoradiotherapy
por: Imai, Hisao, et al.
Publicado: (2022)

Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer
por: Nishioka, Naoya, et al.
Publicado: (2022)

Post‐progression survival is highly linked to overall survival in patients with non‐small‐cell lung cancer harboring sensitive EGFR mutations treated with first‐line epidermal growth factor receptor‐tyrosine kinase inhibitors
por: Imai, Hisao, et al.
Publicado: (2019)

Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing EGFR Mutations
por: Imai, Hisao, et al.
Publicado: (2021)

Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non‐small cell lung cancer
por: Harada, Hideyuki, et al.
Publicado: (2016)

Days Spent at Home near the End of Life in Japanese Elderly Patients with Lung Cancer: Post hoc Analysis of A Prospective Study
por: Notsu, Mikako, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ob20dcvvuqhf5fhmnfpqr66ic3